Results of Operations and Financial Condition. On November 5, 2026, Protagonist Therapeutics, Inc. (the “Company”) reported its financial results for the quarter ended September 30, 2026. A copy of the press release titled “Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update” is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Results of Operations and Financial Condition. On August 5, 2026, Protagonist Therapeutics, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2026. A copy of the press release titled “Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update” is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The filing is about the adoption of a new equity incentive plan and does not involve any changes in management or board composition.

Results of Operations and Financial Condition. On May 5, 2026, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2026. A copy of the press release titled “Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update” is furnished pursuant to

Results of Operations and Financial Condition. On February 25, 2026, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update” is furnished pursuant to

Results of Operations and Financial Condition. On November 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2025. A copy of the press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to

Results of Operations and Financial Condition. On August 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2025. A copy of the press release titled “Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to

Results of Operations and Financial Condition. On May 6, 2025, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025. A copy of the press release titled “Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant to

Other Information. On March 17, 2025, Protagonist Therapeutics, Inc. (the “Company”) and Takeda Pharmaceuticals USA, Inc. (“Takeda”) agreed, pursuant to the provisions of the parties’ License and Collaboration Agreement dated January 31, 2024, as amended, that Takeda will assume responsibility for leading and implementing the regulatory strategy and associated activities for preparation of the New Drug Application related to rusfertide in polycythemia vera to be submitted with the United Stat…

Results of Operations and Financial Condition. On February 21, 2025, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update” is furnished pursuant to

Chief Development Officer — Suneel Gupta: The filing describes an internal title change from Chief Development Officer to Executive Vice President, Clinical Development, which is a role expansion rather than a departure.

Entry into a Material Definitive Agreement On November 13, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) and Janssen Biotech, Inc., a Pennsylvania corporation (“ Janssen ”) entered into an amendment (the “ Amendment ”) to their amended and restated License and Collaboration Agreement dated July 27, 2021 (the “ Collaboration Agreement ”). The Amendment: (a) increases the milestone payment set forth in Section 7.3.1(D) (for a Phase 3 clinical trial for any Licensed Product for any indi…

Results of Operations and Financial Condition. On November 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2024. A copy of the press release titled “Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to

Director — Daniel N. Swisher Jr.: A board member resigned from the board and audit committee, but the event is low materiality as he continues as an advisor and no disagreement was reported.

Results of Operations and Financial Condition. On August 6, 2024, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2024. A copy of the press release titled “Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to

Results of Operations and Financial Condition. On May 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2024. A copy of the press release titled “Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update” is furnished pursuant to

Results of Operations and Financial Condition. On February 27, 2024, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release titled “Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update” is furnished pursuant to

Entry into a Material Definitive Agreement Collaboration and License Agreement On January 31, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”) with Takeda Pharmaceuticals USA, Inc. (“ Takeda ”) for the development, manufacture and commercialization of the Company’s rusfertide product candidate (“ Rusfertide ”) and other specified second-generation injectable hepcidin mimetic compounds (the “ Licensed Pr…

Results of Operations and Financial Condition. On November 2, 2023, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2023. A copy of the press release titled “Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update” is furnished pursuant to

Director — Daniel N. Swisher, Jr.: The filing discloses the appointment of a new independent director to expand the board size, which is a routine governance action rather than an executive departure.

Results of Operations and Financial Condition. On August 3, 2023, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2023. A copy of the press release titled “Protagonist Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update” is furnished pursuant to

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On June 23, 2023, Protagonist Therapeutics, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that following the Company’s Annual Meeting of Stockholders on May 25, 2023, where Sarah Noonberg, M.D., Ph.D. did not stand for re-election, the Company has a vacancy on its Audit Committee and intends to rely on the cure period set forth in the Nasdaq Listing Rules while it recruit…

Results of Operations and Financial Condition. On May 4, 2023, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2023. A copy of the press release titled “Protagonist Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update” is furnished pursuant to

Other Events. Underwriting Agreement On April 4, 2023, Protagonist Therapeutics, Inc. (“ Protagonist ” or the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the public offering, issuance and sale of 5,000,000 shares of the Company’s common stock, par value $0.00001 per share…

Results of Operations and Financial Condition. On March 15, 2023, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2022. A copy of the press release titled “Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update” is furnished pursuant to